STIVARGA® (regorafenib)
STIVARGA is a once-daily, oral prescription anticancer medicine approved by the FDA for people with mCRC, GIST, and HCC
CRC STIVARGA for colon or rectal cancer (CRC)
CRC that has spread to other parts of the body and for which they have received previous treatment with certain chemotherapy medicines.
STIVARGA in mCRCGIST STIVARGA for gastrointestinal stromal tumor (GIST)
A rare stomach, bowel, or esophagus cancer that cannot be treated with surgery or that has spread to other parts of the body and for which they have received previous treatment with certain medicines.
GISTHCC STIVARGA for hepatocellular carcinoma (HCC)
STIVARGA is indicated for patients with a type of liver cancer called hepatocellular carcinoma in people who have been previously treated with sorafenib.
HCC